

TABLE 1 Patient and Transplant Characteristics by Race

	White HCT Recipients N (%)	Black HCT Recipients N (%)	P value
<b>Diagnoses</b>			
Acute myeloid leukemia	97 (41)	28 (49)	0.5
Myelodysplastic syndrome	18 (8)	4 (7)	
Acute lymphoblastic leukemia	123 (52)	25 (44)	
<b>Gender</b>			
Male	140 (59)	34 (60)	1
Female	98 (41)	23 (40)	
<b>Median age years (range)</b>	10 (1-24)	10 (1-29)	0.6
<b>Age (years)</b>			
<10	121 (51)	32 (56)	0.6
≥10	117 (49)	25 (44)	
<b>Median time (months) from diagnosis to transplant (range)</b>	14 (1-125)	11.4 (3-131)	0.8
<b>Recipient Cytomegalovirus serology</b>			
Positive	173 (73)	42 (74)	1
Negative	65 (27)	15 (26)	
<b>Lansky/Karnofsky at Transplant</b>			
≤80	62 (26)	12 (21)	0.5
≥90	176 (74)	45 (79)	
<b>Disease status at transplant ALL or AML</b>			
Complete remission 1 or 2	173 (79)	39 (75)	0.6
Primary Induction failure, third or higher remission, relapse	46 (21)	13 (25)	
<b>Graft Type</b>			
Bone Marrow	136 (57)	28 (50)	0.5
Peripheral Blood	41 (17)	13 (23)	
Umbilical cord	61 (26)	15 (27)	
<b>Donor Relation</b>			
Related	81 (34)	23 (40)	0.5
Unrelated	157 (66)	34 (60)	
<b>HLA Match</b>			
Fully matched (8/8 BM PB or 6/6 UCB)	107 (47)	16 (29)	0
Mismatched (<8/8 BM PB or <6/6 UCB)	119 (53)	39 (71)	
<b>HLA Match/relation/source</b>			
Matched sibling BM or PB	44 (20)	8 (15)	0.2
1 antigen mismatched related donor BM or PB	3 (1)	1 (2)	

Matched unrelated donor BM or PB	54 (24)	8 (15)	
Mismatched unrelated donor (<8/8 Ag match) BM or PB	38 (17)	9 (16)	
Mismatched related/haploidentical donor (>2 Ag mismatched) BM or PB	32 (14)	14 (26)	
Matched related or unrelated cord blood (6/6 Ag match)	9 (4)	0 (0)	
Mismatched cord blood (<6/6 Ag match)	46 (20)	15 (27)	
<b>Donor-Recipient gender match</b>			
Male to male or Female to female	106 (51)	24 (50)	1
Male to female or Female to male	102 (49)	24 (50)	
<b>Donor-Recipient Cytomegalovirus serology match</b>			
Pos-pos or Neg-neg	131 (58)	34 (63)	0.5
Pos-neg or Neg-pos	95 (42)	20 (37)	
<b>Conditioning Regimens ALL</b>			
TBI- based (TBI±Cyclophosphamide±Fludarabine±Thiotepa)	101 (82)	22 (88)	0.76
Thiotepa/Melphalan/Fludarabine	9 (7)	1 (4)	
Other combinations of chemotherapy agents	13 (11)	2 (8)	
<b>Conditioning Regimens AML/MDS</b>			
Busulfan/Fludarabine	45 (39)	15 (47)	0.9
Busulfan/Cyclophosphamide	32 (28)	5 (16)	
Thiotepa/Melphalan/Fludarabine	19 (17)	3 (9)	
TBI-based	7 (6)	4 (13)	
Other	12 (10)	5 (16)	
<b>Conditioning Intensity</b>			
Myeloablative	235 (99)	54 (95)	0.2
Reduced intensity	2 (1)	1 (2)	
Non-myeloablative	1 (0)	2 (4)	
<b>Anti-thymocyte globulin used in conditioning</b>			
Yes	112 (47)	22 (39)	0.3
No	126 (53)	35 (61)	
<b>Rituximab used in conditioning</b>			
Yes	55 (23)	14 (25)	0.9
No	183 (77)	43 (75)	
<b>Cumulative Number of Comorbidities Prior to Transplant</b>			
0-1	184 (78)	45 (79)	1
2 or more	52 (22)	12 (21)	
<b>Year of Transplant</b>			
2010-2012	53 (22)	8 (14)	0.4
2013-2015	89 (37)	22 (39)	
2016-2019	96 (40)	27 (47)	
<b>Center</b>			
1	81 (34)	11 (19)	0.2

2	29 (12)	8 (14)	
3	44 (19)	11 (19)	
4	58 (24)	16 (28)	
5	26 (11)	11 (19)	

ALL = acute lymphoblastic leukemia

AML = acute myeloid leukemia

MDS = myelodysplastic syndrome

BM = bone marrow

PB = peripheral blood

UCB = umbilical cord blood

TBI = total body irradiation